^
    Apply
    CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease (NCT03618641)
    Phase 2
    Diwakar Davar
    Completed
    Last update posted :
    02/07/2025
    Initiation :
    08/08/2018
    Primary completion :
    08/20/2020
    Completion :
    12/31/2023
    CD8 • CD4 • SOX10
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)
    A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma (NCT04708418)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/15/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    Keytruda (pembrolizumab) • vidutolimod (CMP-001) • Pembroria (pembrolizumab biosimilar)
    Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) (NCT05061017)
    Phase 2
    Diwakar Davar
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    12/09/2021
    Primary completion :
    02/05/2024
    Completion :
    03/18/2024
    KRAS • BRAF • ALK • MET
    |
    KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • cyclophosphamide intravenous • pixatimod (PG545)
    Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab (NCT04401995)
    Phase 2
    Diwakar Davar
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    09/02/2020
    Primary completion :
    07/30/2028
    Completion :
    07/30/2028
    CD8
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)
    Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    10/29/2012
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    HLA-DRB1
    |
    PD-1 expression
    |
    Promune (agatolimod)
    CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (CMP-001-007) (NCT04633278)
    Phase 2
    Regeneron Pharmaceuticals
    Completed
    Last update posted :
    02/02/2024
    Initiation :
    01/21/2021
    Primary completion :
    01/19/2024
    Completion :
    01/19/2024
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • vidutolimod (CMP-001)
    Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors (PERIO-02) (NCT05220722)
    Phase 1/2
    TriSalus Life Sciences, Inc.
    Active, not recruiting
    Last update posted :
    12/25/2023
    Initiation :
    03/02/2022
    Primary completion :
    12/01/2023
    Completion :
    01/01/2025
    FGFR2
    |
    FGFR2 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • nelitolimod (SD-101)
    Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer (NCT00292045)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/04/2023
    Initiation :
    10/27/2004
    Primary completion :
    01/09/2006
    Completion :
    01/09/2006
    CD8 • CTAG1B
    |
    Promune (agatolimod)
    A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer. (NCT00199836)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    09/03/2003
    Primary completion :
    09/05/2005
    Completion :
    06/06/2006
    CD8 • CTAG1B • CTAG2
    |
    HLA-A2 positive
    |
    Promune (agatolimod)
    NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors (NCT00299728)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    03/21/2006
    Primary completion :
    10/10/2006
    Completion :
    01/10/2014
    CTAG1B • CD4 • CTAG2
    |
    CTAG1B expression • CTAG2 expression
    |
    Promune (agatolimod)
    Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer (CMP-001-003) (NCT03438318)
    Phase 1b
    Regeneron Pharmaceuticals
    Completed
    Last update posted :
    08/03/2022
    Initiation :
    03/15/2018
    Primary completion :
    12/11/2019
    Completion :
    12/11/2019
    EGFR • ALK
    |
    EGFR mutation • EGFR T790M
    |
    Tecentriq (atezolizumab) • vidutolimod (CMP-001) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma (ILLUMINATE 204) (NCT02644967)
    Phase 2
    Idera Pharmaceuticals, Inc.
    Completed
    Last update posted :
    08/03/2022
    Initiation :
    12/01/2015
    Primary completion :
    02/01/2020
    Completion :
    05/01/2021
    BRAF
    |
    BRAF mutation • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • tilsotolimod (IMO-2125)
    CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) (NCT04807192)
    Phase 2
    Centre Hospitalier Universitaire Vaudois
    Recruiting
    Last update posted :
    07/09/2021
    Initiation :
    04/08/2021
    Primary completion :
    09/01/2023
    Completion :
    12/01/2025
    HER-2 • ER • PGR
    |
    vidutolimod (CMP-001)
    CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors (NCT00819806)
    Phase 1
    Hassane M. Zarour, MD
    Completed
    Last update posted :
    07/31/2017
    Initiation :
    01/01/2009
    Primary completion :
    05/01/2012
    Completion :
    01/01/2015
    CTAG1B
    |
    CTAG1B expression
    |
    cyclophosphamide • Promune (agatolimod) • cyclophosphamide intravenous
    Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma (NCT00438880)
    Phase 1/2
    Mayo Clinic
    Completed
    Last update posted :
    02/04/2016
    Initiation :
    10/01/2004
    Primary completion :
    10/01/2010
    Completion :
    11/01/2014
    CD20
    |
    Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan) • Novex (rituximab biosimilar) • Promune (agatolimod)
    A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer. (NCT00471159)
    Phase 2
    Pfizer
    Withdrawn
    Last update posted :
    05/04/2015
    Initiation :
    08/01/2007
    HER-2
    |
    HER-2 negative
    |
    docetaxel • Promune (agatolimod)